A Phase 3 interventional study of ABBV-444 in Dry Eye Syndrome, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Dry Eye Syndromes by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · AbbVie.
Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 32nd largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2023, is one of 12 in phase 3, and was the 44th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →1 of the 48 studies in Dry Eye Syndromes by AbbVie is open now, in 3 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, France, Netherlands
Ages 18–75
By country, each count listing its studies:
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 13 · Phase 4 9
First in 2001; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 80 across the 40 interventional studies, 128 across the 8 observational. Of the 47 that completed or were terminated, 40 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 48 studies in Dry Eye Syndromes by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate symptom relief and tolerability of ABBV-444 eye drops in adult participants.
ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). This is a 30-day, open-label study to evaluate adult participant symptoms and tolerability of ABBV-444. Around 40 participants will be enrolled in 1 site in the United States.
Participants will receive 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will administer 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days.
Drug: ABBV-444
Lubricant Eye drops
Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score
The OSDI is a 12-question survey for participants to document their dry eye disease symptoms. The OSDI consists of a 5-point scale ranging from 0 (none of the time) to 4 (all of the time), with higher scores representing greater disability. The scores from the 12 questions are totaled and converted to an overall score ranging from 0 (no disability) to 100 (complete disability). A negative number change from baseline represents an improvement.
Time frame: Baseline to Day 30
Patient Eye Drop Experience (PEDE) Survey Scores at Day 30 (Visual Analog Scale)
The PEDE Survey is a 13-item questionnaire that evaluates the short- and long-term subjective experience in comfort and vision as well as tolerability, using a scale ranging from 0 (strongly disagree) to 100 (strongly agree). On Day 30, participants were asked to retrospectively recall their experiences after 5 minutes, 30 minutes, 24 hours, and 5 days of when they administered the eye drops
Time frame: Day 30
Change From Baseline in Symptom Scores (Visual Analog Scale) Within 5 Minutes Post Administration of ABBV-444
The Current Symptom Survey is a 5-item questionnaire where the participants rate their ocular symptoms at the present moment using a scale ranging from 0 (strongly disagree) to 100 (strongly agree). Surveys were completed 5 minutes following the first administration of study eye drops. A negative number change from baseline represents an improvement.
Time frame: Baseline (T0) to 5 minutes (T5)
A total of 40 participants were enrolled and included in the intent-to-treat (ITT) population. The per-protocol (PP) population included 34 participants after excluding 4 participants who were deemed protocol deviations and 2 participants who discontinued the study. The per-protocol population was used for all efficacy measures.
| Milestone | ABBV-444 |
|---|---|
| Started | 40 |
| Completed | 38 |
| Not completed | 2 |
| Withdrew: Lost to follow-up | 2 |
The OSDI is a 12-question survey for participants to document their dry eye disease symptoms. The OSDI consists of a 5-point scale ranging from 0 (none of the time) to 4 (all of the time), with higher scores representing greater disability. The scores from the 12 questions are totaled and converted to an overall score ranging from 0 (no disability) to 100 (complete disability). A negative number change from baseline represents an improvement.
| score on a scale | ABBV-444 |
|---|---|
| Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score | -6.8 ± 15.0 |
The PEDE Survey is a 13-item questionnaire that evaluates the short- and long-term subjective experience in comfort and vision as well as tolerability, using a scale ranging from 0 (strongly disagree) to 100 (strongly agree). On Day 30, participants were asked to retrospectively recall their experiences after 5 minutes, 30 minutes, 24 hours, and 5 days of when they administered the eye drops
| score on a scale | ABBV-444 |
|---|---|
| The study eye drops do not cause stinging or burning in my eyes (5 minutes) | 76.4 ± 36.7 |
| Study eye drops provided immediate relief of my eye dryness when putting in my eyes (5 minutes) | 77.1 ± 27.9 |
| Study eye drops immediately soothed my eye dryness when putting in my eyes (5 minutes) | 81.3 ± 25.3 |
| Did not experience much blurry/fluctuating vision after putting study eye drops in my eyes (5 mins) | 77.5 ± 30.4 |
| Study eye drops provided immediate comfort to my eye dryness when putting in my eyes (5 minutes) | 84.1 ± 21.1 |
| The study eye drops are very soothing for my eye dryness (30 minutes) | 82.0 ± 25.6 |
| The study eye drops did not feel sticky (30 minutes) | 78.6 ± 30.8 |
| The study eye drops continued to provide relief of my eye discomfort (30 minutes) | 84.6 ± 20.7 |
| The study eye drops continued to provide comfort to my eye dryness (30 minutes) | 85.7 ± 21.0 |
| The study eye drops provided relief of my eye dryness day and night (24 hours) | 84.4 ± 20.0 |
| The study eye drops provided comfort to my eye dryness day and night (24 hours) | 84.5 ± 21.5 |
| The study eye drops provided lasting relief of my eye dryness (5 days) | 83.8 ± 23.2 |
| The study eye drops have provided relief during conditions that lead to eye dryness (5 days) | 82.0 ± 22.6 |
The Current Symptom Survey is a 5-item questionnaire where the participants rate their ocular symptoms at the present moment using a scale ranging from 0 (strongly disagree) to 100 (strongly agree). Surveys were completed 5 minutes following the first administration of study eye drops. A negative number change from baseline represents an improvement.
| score on a scale | ABBV-444 |
|---|---|
| Change From Baseline in Symptom Scores (Visual Analog Scale) Within 5 Minutes Post Administration of ABBV-444 | -10.1 ± 10.6 |
Collected over All-cause mortality and adverse event tables include events reported from enrollment to end of study. Safety events (per protocol) were collected from enrollment through the 30 day treatment period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABBV-444 | 0/40 (0%) | 0/40 (0%) | 0/40 (0%) |
ITT population: Includes all enrolled participants who received at least one dose of study drug
| Age, Continuous(years) | ABBV-444 |
|---|---|
| Mean | 37.7 ± 15.8 |
| Sex: Female, Male(Participants) | ABBV-444 |
|---|---|
| Female | 24 |
| Male | 16 |
| Ethnicity (NIH/OMB)(Participants) | ABBV-444 |
|---|---|
| Hispanic or Latino | 38 |
| Not Hispanic or Latino | 2 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | ABBV-444 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 38 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jun 2023 to primary completion in Oct 2023, 3 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 3 months is below that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.